The target patient group is determined based on the results of clinical trials. Particularly, patients with severe diabetes or those who have not improved with other treatments may be prioritized.
KIYAN Group and Collaborating Research Institutions
Biozipcode, Inc.
We aim to completely cure diseases rather than just offering symptomatic treatments. We focus on developing a cure for diabetes and a technology that delivers medication to specific cells (cell targeting technology called “Biozipcode”).
Learn More About Us
Contact Us
Biozipcode, Inc.
TEL:
+81-50-5534-7865
E-MAIL:
info@biozipcode.com
ADDRESS:
Seta Tsukiwa-cho, Otsu City, Shiga Prefecture
Biomedical Innovation Center, Shiga University of Medical Science, 520-2121
© Copyright 2024 Biozipcode, Inc. All Rights Reserved.